JAK1 and tuberculosis: Dear Editor, We report on a 68-year-old Caucasian male with a 6-year history of PsA who developed pulmonary and lymph node tuberculosis (TB) 6 months after initiation of treatment with the Janus kinase 1 (JAK1) inhibitor upadacitinib.